Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA) announced its participation in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. CEO Todd Harris will be featured in a panel on March 8, 2022, at 9:10 am ET. The event aims to highlight the company's focus on precision oncology and its proprietary SNÅP platform to develop therapies targeting tumor resistance. Investors can access a live webcast on the company's website. Tyra specializes in inhibitors for the Fibroblast Growth Factor Receptor (FGFR) family, crucial in treating various cancers.

CARLSBAD, Calif., Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be participating in a corporate panel discussion at the Cowen 42^nd Annual Healthcare Conference, taking place virtually March 7-9, 2022.  Details are below: 

Corporate Panel Details:

• Targeted Oncology – Todd Harris, CEO of TYRA
• Tuesday, March 8, 2022, 9:10 am ET

A live webcast of the panel will be available on the Company's website at https://tyra.bio in the "For Investors" section.

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors. 

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. TYRA cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. TYRA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of TYRA in general, see the risks described in our prior filings with the U.S.  with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our most recent quarterly report on Form 10-Q and any subsequent filings with the SEC.

Contact:
Amy Conrad
aconrad@tyra.bio

View original content:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-in-cowen-42nd-annual-healthcare-conference-301487891.html

SOURCE Tyra Biosciences

FAQ

When is Tyra Biosciences participating in the Cowen Healthcare Conference?

Tyra Biosciences will participate in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022.

Who is representing Tyra Biosciences at the conference?

CEO Todd Harris will represent Tyra Biosciences during the panel discussion.

What time is Tyra's panel discussion scheduled?

The panel discussion is scheduled for March 8, 2022, at 9:10 am ET.

How can I watch the Tyra Biosciences conference panel?

A live webcast of the panel will be available on Tyra Biosciences' website in the 'For Investors' section.

What is the focus of Tyra Biosciences' research?

Tyra Biosciences is focused on developing therapies to overcome tumor resistance using its SNÅP platform.

What types of inhibitors is Tyra developing?

Tyra is developing selective inhibitors targeting the Fibroblast Growth Factor Receptor (FGFR) family.

What is the significance of FGFR in cancer treatment?

Alterations in FGFR are found in approximately 7% of all cancers, making them a target for treatment.